Figure 1.

Disposition of patients in the study. *One patient was nonrandomly assigned to Arm A and received treatment with motesanib 125 mg QD. ^†Total shown does not reflect 2 additional patients who discontinued motesanib for other reasons but later were granted a waiver to continue in a rollover study.